Courtagen Life Sciences Announces Collaboration with Raptor Pharmaceuticals
News Mar 26, 2014
Courtagen Life Sciences has announced an agreement with Raptor Pharmaceuticals Inc. to provide genetic testing in the clinical trial for RP103 as a potential treatment for Leigh syndrome and other mitochondrial disorders.
Leigh syndrome is a severe neurological disorder caused by genetic defects in mitochondrial or nuclear DNA affecting respiratory chain function that typically results in death within the first decade of life.
“The genetic profiling of patients is expected to elucidate important information beneficial to Raptor’s clinical trial for RP103,” said Brian McKernan, CEO of Courtagen.
McKernan continued, “We are pleased to work with Raptor Pharmaceuticals and believe that Courtagen’s mtSEEK® and nucSEEK® Next Generation Sequencing tests offer the most comprehensive mitochondrial analysis for such clinical trial work.”
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Comments | 0 ADD COMMENT
10th Annual Congress on Drug Formulation & Analytical Techniques
Sep 03 - Sep 04, 2018